Friedreich ataxia is an autosomal-recessive, neurodegenerative disease that primarily affects the nervous system and heart. It was named after Nicolaus Friedreich, a Professor of Medicine in ...

Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, progressive neurodegenerative disease, in individuals aged 16 years and above. The ...

SINCE Friedreich's original description 1 of 6 cases of familial hereditary ataxia in 1863, numerous papers have been written on this subject. The vast majority of these elaborate on the ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

At this point, there are several therapies which are coming along, a large trial called the ExRx trial, which included the nutraceutical, nicotinamide riboside has finished. The data are not yet ...